Bicara Therapeutics Inc. (BCAX)
Technology · NasdaqGM · US
Fundamentals
Valuation and ratings
Bicara Therapeutics Inc. trades at USD27.60. We do not hold enough of the inputs to run a discounted cash flow on this company, so we publish no fair value for it rather than a number we would not defend.
About Bicara Therapeutics Inc.
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
BCAX passes 1 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Smart money ownership
5 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Ken Griffin, CITADEL ADVISORS LLC$33.00M · 0.0% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$5.51M · 0.0% of book
- Israel Englander, MILLENNIUM MANAGEMENT LLC$3.12M · 0.0% of book
- Two Sigma, TWO SIGMA INVESTMENTS, LP$1.79M · 0.0% of book
- Cliff Asness, AQR CAPITAL MANAGEMENT LLC$262.3K · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
Common questions
Which funds own BCAX?
5 of the institutions we track reported a position in BCAX in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
The full research page for BCAX, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.